Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
581-600 of 2,251 trials

Advanced Urothelial Carcinoma: MK-2870 with Enfortumab Vedotin

We are studying a new treatment combining MK-2870 with Enfortumab Vedotin and Pembrolizumab for patients with advanced bladder cancer. The goal is to assess safety and how well it works compared to existing options.

Bladder Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Immuno-OCT Imaging: Safety and Feasibility Study

We are exploring a new imaging technique using a tracer for patients undergoing endoscopy. The goal is to determine if this method is safe and effective for better visualization during procedures.

Barrett's EsophagusColon CarcinomaGastrointestinal DysplasiaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Melanoma, NSCLC, and Cervical Cancer: ANV419 vs High-Dose IL-2

We are studying whether a new treatment (ANV419) is safer and improves outcomes compared to high-dose IL-2 for patients after tumor-infiltrating lymphocyte therapy. This trial also looks at quality of life and patient experiences.

Advanced Solid Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Chronic Lymphocytic Leukemia: New Triple Therapy Study

We are testing a new combination of medications for patients with high-risk chronic lymphocytic leukemia who haven't been treated before. The study aims to see if this new treatment can help keep the disease from progressing better than standard options.

High-Risk Hematological Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Chronic Kidney Disease: FINESSE Study on Albuminuria Reduction

We are researching how well finerenone and semaglutide can lower albuminuria in patients with chronic kidney disease. The goal is to find the most effective treatment for each individual and explore remote monitoring options.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyNephrology

Preventing Diabetes After Kidney Transplant: GLP-1 Medication Study

We are testing whether GLP-1 receptor agonists can help reverse metabolic syndrome in patients on the kidney transplant waiting list. This study will evaluate changes in health and safety over 3 to 6 months.

Metabolic Syndrome in Kidney Transplant Patients3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Preventing Diabetes After Kidney Transplant: GLP-1 Treatment Study

We are studying whether a new medication can help prevent diabetes in patients immediately after receiving a kidney transplant. This trial looks at various health effects and safety over time.

Post-Kidney Transplant Diabetes>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesDiabetologyNephrology

Ulcerative Colitis: Comparing Ustekinumab and Infliximab

We are studying whether a combination of two treatments helps people with moderate to severe ulcerative colitis achieve remission better than using each treatment alone.

Ulcerative Colitis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Repotrectinib for Advanced Cancers in Kids and Young Adults

We are studying a new treatment for children and young adults with advanced cancers that have specific genetic changes. The trial aims to evaluate how well it works and its safety.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Liver Transplant: Low-Dose Arginine-Vasopressin Study

We are investigating whether low-dose arginine-vasopressin can reduce kidney injury after liver transplantation. This study aims to improve recovery and outcomes for transplant patients.

Acute Kidney InjuryLiver Transplantation≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHepatologyNephrology

Colorectal Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab alone and with standard chemotherapy for patients with advanced colorectal cancer. The goal is to see how well it works and to ensure it is safe.

Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Parkinson's Disease: AAV2-GDNF Treatment Study

We are studying a new therapy to see if it can improve motor symptoms in adults with moderate Parkinson's Disease. The trial also looks at safety and overall quality of life for participants.

Parkinson's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurology

Severe Hemophilia A: Continued Access to Efanesoctocog Alfa

We are providing ongoing treatment access for patients with severe hemophilia A who completed a previous trial with efanesoctocog alfa. The study aims to gather more information on its safety and effectiveness in preventing and treating bleeding episodes.

Haemophilia AConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Teicoplanin for Infection Prevention in Pediatric AML

We are studying whether teicoplanin can help prevent serious infections in children newly diagnosed with acute myeloid leukemia. This trial will assess its safety and effectiveness during their treatment.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesOncology

Mycobacterium abscessus: Optimizing Lung Disease Treatment

We are studying the best treatment options for lung disease caused by Mycobacterium abscessus. Our goal is to see how well these treatments clear the infection and how well patients tolerate them.

Mycobacterium Abscessus Infection1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesPulmonology

Acute Leukemia: Bleximenib Study

We are testing a new drug called Bleximenib for people with acute leukemia to find the best dose and check its safety. We also want to see if it helps improve treatment outcomes.

Acute Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematology

Acute Myeloid Leukemia: Bleximenib Treatment Study

We are testing a new drug, bleximenib, combined with current therapies for patients with acute myeloid leukemia who have certain genetic changes. The goal is to find the best dose and ensure it is safe for use.

Acute Myeloid Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Large-Cell Neuroendocrine Carcinomas: Durvalumab Combination Therapy

We are studying a new treatment combining durvalumab with etoposide and platinum for patients with advanced large-cell neuroendocrine carcinomas of the lung. The goal is to evaluate its effectiveness and safety compared to standard treatments.

Large-Cell Neuroendocrine Carcinoma of the LungLocally Advanced or Metastatic Lung Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Early Rectal Cancer: FARE Trial with [68Ga]Ga-FAPI-46 PET/CT

We are studying a new imaging method to detect lymph node spread in early rectal cancer patients. This trial aims to see if it provides more accurate results than standard imaging techniques.

Rectal Cancer≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInfectious DiseasesInternal MedicineOtolaryngology

Liver Transplant: Single vs. Twice Daily Immunosuppressive Doses

We are studying whether a single daily dose of immunosuppressive medication is as effective as a twice-daily dose for liver transplant recipients. This trial also compares two different formulations of tacrolimus to see which works better.

Transplantation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHepatologyInternal Medicine